Navigation Links
Key research from the 2012 Breast Cancer Symposium highlights treatment advances for early breast cancer
Date:9/12/2012

ALEXANDRIA, Va. Four new studies on the treatment of early breast cancer, spanning from diagnosis through surgery, were released today in advance of the 2012 Breast Cancer Symposium. The Symposium will take place September 13-15, 2012, at the San Francisco Marriott Marquis in San Francisco.

Four major studies were highlighted in today's presscast:

  • A new device may reduce the need for follow-up surgeries after lumpectomy, helping preserve the cosmetic appearance of the breast: A large clinical trial determined that an investigational device that helps ensure sufficient tissue is removed during a lumpectomy, results in fewer additional surgeries, without the cost of having to remove larger amounts of tissue.

  • Study refines risk of recurrence and death in patients with estrogen-receptor positive breast cancer that has spread to axillary lymph nodes: The study showed that a 21-gene recurrence score predicts favorable and unfavorable outcomes after chemotherapy and adjuvant hormonal therapy, which helps with tailoring the dose of adjuvant therapy and selecting patients who might benefit from novel therapies.

  • Routine screening using liver ultrasound, bone scan, and chest X-ray is of little value for detection of breast cancer metastases: A comprehensive literature review found that the three radiological tests detect metastases very rarely, raising concerns about their continued use in routine screening, particularly for patients with early-stage breast cancer.

  • Women with stage II breast cancer who are at high risk of residual nodal disease may benefit from axillary lymph node removal: Results of a study simulating axillary recurrence risk, lymphedema, and quality of life determined that women may want to consider axillary lymph node removal if they are at high risk of residual nodal disease after breast conserving surgery and treatment with whole-breast radiation.

"Advances in precision medicine have lead to identifying the best course of treatment for each individual patient. The research presented today adds to this growing knowledge base by confirming which patient populations are most likely to benefit from screening interventions and surgical procedures," said Andrew Seidman, MD, American Society of Clinical Oncology Cancer Communications Committee member. "These studies will help physicians feel more confident in their treatment decisions while maximizing the benefits to patients."

An estimated 226,870 new cases of invasive breast cancer are expected to occur in women in the United States, and another 2,190 cases are expected in U.S. men in 2012. An additional 63,300 cases of in situ (non-invasive) breast cancer are expected to occur in U.S. women as well, totaling more than 290,000 new cases.*

This year's Breast Cancer Symposium will include more than 200 abstracts and focus on taking the latest scientific results in the field and bringing them into the clinic for practical applications. Sessions will cover a range of topics such as risk assessment, detection and screening, survivorship and systemic therapy.


'/>"/>
Contact: Kelly Baldwin
kelly.baldwin@asco.org
571-483-1365
American Society of Clinical Oncology
Source:Eurekalert

Related medicine news :

1. Local talent: Global impact public invited to meet world-class researchers at Queens
2. Scripps Research scientists devise powerful new method for finding therapeutic antibodies
3. Researchers improve gene therapy technique for children with immune disorder
4. Hospital for Special Surgery investigators receive National Football League grant for PRP research
5. Obesity research wins Fernström Prize
6. Moffitt researchers say race affect likelihood of finding suitable stem cell donor
7. Researchers closer to understanding actions of cells involved in atherosclerosis
8. Metabolic engineer synthesizes key breast milk ingredient, makes research possible
9. Case Western Reserve researchers create short-term memories in-vitro
10. Researchers find first evidence for a genetic cause for Barretts esophagus
11. MBL and Stanford scientists receive 2012 Lasker Award for Basic Medical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... ... Nutrition Education for the Public (NEP), a dietetic practice ... Nutrition Partnership (SNP) in presenting “Eating Heart Healthy: Exploring Issues of Low Seafood ... inform consumers about the health benefits of eating a seafood-rich diet. , ...
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... ... organizations submitted a letter to President Trump expressing their support for an independent ... doctors, two Ph.D. scientists and one medical journalist, will hold a press conference ...
(Date:3/29/2017)... ... ... ARI Network Services, Inc. (NASDAQ: ARIS) announced today that Rhino Ag has named ... more than 650 U.S.-based dealers. Rhino, a member of the Alamo Group, offers a ... cutters, rear blades, post hole diggers, pasture renovators, tillers, disc mowers and box blades. ...
(Date:3/29/2017)... York City, NY (PRWEB) , ... March 29, ... ... body for men’s and women’s professional squash, announced it has enlisted New York ... partner. The agency will develop and procure sponsorship opportunities for the Professional ...
(Date:3/29/2017)... , ... March 30, 2017 , ... Grass pollen is the main cause of hay ... the stuff. The season for grass pollen runs from May to July each year; with ... fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... SAN DIEGO , March 29, 2017 Avelas Biosciences, ... care from diagnosis through treatment, today announced that Carmine N. ... of the company at the Needham & Company 16 th ... EDT (8:20 a.m. PDT) at the Westin Grand Central Hotel in ... Biosciences ...
(Date:3/29/2017)... Today, CVS Health officials (NYSE: CVS ... of Public Health Director Gerd Clabaugh and Office ... announcing the availability of the opioid overdose-reversal medicine naloxone without ... Health has established a standing order with physicians in ... access to the medication in the state.   ...
(Date:3/29/2017)... WALNUT CREEK, Calif. , Mar 29, 2017 ... tissue-sparing, cervical-fusion technology, announced the addition of two ... Scott Lynch has joined the company to ... is assuming International leadership.  Together, Mr. Lynch and ... industry experience.  Mr. Lynch joins ...
Breaking Medicine Technology: